Easier access to medicines and technology would improve health outcomes in Central and Eastern Europe. Prioritising cost saving measures in the short-term ignores the benefits of new technologies on both healthcare costs and patient outcomes in the long-term. In order to ensure equal access to innovative medicines across Europe, Central and Eastern European governments should consider measures like reference pricing and health technology assessments. Improving access while bringing down costs will also require coordination and transparency with multiple stakeholders within each country and across the region. Read our publication with Economist Impact for more.
Improving access to medical innovation in Central and Eastern Europe
Easier access to medicines and technology would improve health outcomes in Central and Eastern Europe. Prioritising cost saving measures in the short-term ignores the benefits of new technologies on both healthcare costs and patient outcomes in the long-term. In order to ensure equal access to innovative medicines across Europe, Central and Eastern European governments should consider measures like reference pricing and health technology assessments. Improving access while bringing down costs will also require coordination and transparency with multiple stakeholders within each country and across the region. Read our publication with Economist Impact for more.
Related items
:focal())
News
20 May 2026
Healthcare, competitiveness, innovation and simplification
Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation.
The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment.
The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains.
:focal())
Position Paper
19 May 2026
Strengthening EU competitiveness through an adaptive MDR/IVDR framework
Position Paper
19 May 2026
A global approach to strengthening Europe’s biotechnology ecosystem
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.